EDAP TMS Draws EIB Tranche, Issues New Warrants

An announcement from EDAP TMS ( (EDAP) ) is now available.

EDAP TMS S.A. has drawn a €12.0 million second tranche under its previously announced €36.0 million credit facility with the European Investment Bank, after satisfying the required conditions, with the funds requested on April 1, 2026 and expected to be disbursed in late April 2026. The Tranche B loan will mature five years after disbursement with interest due at maturity, and in connection with this financing EDAP issued 1,116,244 warrants to the EIB on April 1, 2026 at a strike price of €3.23 per share, a structure that strengthens the company’s liquidity while introducing potential future equity dilution for shareholders.

The most recent analyst rating on (EDAP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on EDAP TMS stock, see the EDAP Stock Forecast page.

Spark’s Take on EDAP Stock

According to Spark, TipRanks’ AI Analyst, EDAP is a Neutral.

The score is held back primarily by weak financial performance (sizable losses, negative cash flow, shrinking equity) and soft near-term technicals. These are partially offset by a constructive earnings call with reiterated high-growth 2026 HIFU guidance and strong core commercial momentum, while valuation remains difficult to assess due to negative earnings.

To see Spark’s full report on EDAP stock, click here.

More about EDAP TMS

EDAP TMS S.A. is a medical technology company focused on therapeutic ultrasound solutions, including minimally invasive treatments using high-intensity focused ultrasound and related devices for urological and other applications. The company targets global healthcare providers seeking advanced, non-invasive treatment options that can improve patient outcomes and expand procedural capabilities.

Average Trading Volume: 68,168

Technical Sentiment Signal: Hold

Current Market Cap: $132.3M

See more insights into EDAP stock on TipRanks’ Stock Analysis page.